Cost is a factor in the choice of prosthetic components in joint replacement. For a given performance, the least expensive components are the most cost-effective. When evaluating a new prosthesis with an unknown outcome, the use of an economic model allows estimation of potential cost-effecfiveness. We used published data for the survival of cemented total hip replacementsfrom Sweden, and cost and demographic information from New South Wales, Australia, in such a model. I.n young active total hip recipients a new prosthetic design which offered a 90% improvement in survivorship over 15 years and a 15% reduction in the cost of revision surgery, could be sold at a price of 2 to 2.5 times that of conventional cemented components such as the Charnley Low Friction Arthroplasty and still be cost-effective. Using more likely estimates of the improved performance of new technology, however, the upper limit of cost-effectiveness is an increase of 1.5 to 1. Only a very small increase in the cost of a prosthesis could ever be justified for older patientsof either sex. 
designs have been introduced. Most have avoided compar ative evaluation of outcome by randomised controlled trials by application of the principle of â€˜substantial equivalence' (Faro and Huiskes 1992) and have been put into use in the expectation of improved results. Although based on exten sive biological and biomechanical research their expecta tions may not be fulfilled, as illustrated by the history of surface replacement of the hip in the early 1980s (Dorey and Amstutz 1989) . The price of many newer designs is over three times that of proven cemented components, yet the proposed benefits remain unsubstantiated.
Surgeons should therefore consider carefully what the individual patient and society at large are receiving for their investment, and whether the additional costs of the pros thesis are justified (Bulstrode et al 1993) . Perhaps the new technology should be withheld from general use until out come data, including analysis of cost-effectiveness, are available from comparative studies, as is now the case for new drugs in many countries (Freemantle et al 1995) .
Another approach is to model cost-effectiveness, compar ing the hypothetical performance with direct observation of existing prosthetic designs.
We have used a model described by Daellenbach et al (1990) to examine long-term outcome data, and the choices which orthopaedic surgeons and others must make.
METhOD
The model assumes that the clinical result of a THR remains acceptable until revision is required and that increased expenditure on the prosthesis is only justifiable if accompanied by a proportional improvement in survival. The possible benefits of a new ThR include reduced costs of implantation (including prosthetic and all other hospital costs), longer clinical survival and easier, less expensive revision surgery. In this simple form of the model, equiva lence of hospital costs other than that of the prosthesis is assumed. The Present Value (PV) of the implantation of a prosthesis of known cost and survivorship is compared with that of a new prosthesis, for which the pricing indicates extra cost in the current period. Estimates of future savings â€˜Cross-over' ages may also be calculated; these are the ages below which a given increase in prosthetic expendi ture would be justified (Daellenbach et al 1990) .
For this particular application of the model, the PV of where PVc = expected present value of cost of treating a patient with prosthesis C over n years; Cc = cost of pros thesis C; H = hospital costs of first operation; urn = prob ability of individual in age group m being alive at year i; 
RESULTS

Break-evenprostheticprice ratios.TablesI andII show
by gender, the prosthetic price ratios which achieve the break-even point for options C and E at 5, 9 and 15 years, and are derived by using each of four hypothetical rates of prosthetic failure and two assumptions about the cost of revision surgery. We modelled equivalent failure rates (FE FC) and three possible outcomes in which the failure rate of the new technology was 80%, 50% or 10% of that of the conventional at each point of measurement over 15 years (i.e., FE:FC 0.8, 0.5 and 0. 1). We assumed that the costs of revision were equal (RE = Râ‚¬) or that the cost of revision surgery was reduced by $1500, approximately Table  I 15% of the total, if the new technology had been used for the primary replacement (RE = R@â€" $ 1500). The ratio expresses the price CE which could be justified. Over periods of 5 and 9 years only modest increases in price ratio would prove cost-effective and over 15 years price ratios of over 2 to 1 would be acceptable if the revision rate was reduced by 90%. Significant reduction in the cost of revision, however, is unlikely, and a fall in the present failure rate of more than 50% is improbable using any components for which early results are available. Thus, only price rises of the order of 70% over those of good, established â€˜first-generation' components are likely to prove cost-effective in the younger age groups. In older patients, only very small increases in expenditure on pros thetic components could ever be justified, which is what would be expected in the context of shorter life expectancy and high survivorship of the replacement.
Effect of varying prosthetic cost on the output of an orthopaedic unit. In Table III it is assumed that a new prosthesis E is available at the same price as prosthesis C but has an improved survival profile. For each of i years 100 first operations of present value PVC6 have been performed after which a number of reoperations, dependent on the published survival profile for the age group for prosthesis C, of present value @ will be necessary. Had prosthesis E been used, its improved performance would have reduced the number of revisions necessary in the period, allowing more first operations for the same overall expenditure. The benefits from additional first operations would be significant.
The effect of introducing a new prosthesis E available at twice the price of prosthesis C is very different. Table IV shows that, despite improved survival profiles, a policy of using E rather than C is reflected in a reduction in the numbers of first operations for each reoperation prevented. years should be used to decide if the trial is justified. The information in Table I shows that a randomised trial recruit ing men and women under the age of 75 years would be appropriate in the case of a new component system priced at 1.4 times C@ for which a plausible claim is made of a 50% reduction in prosthetic failure rate at 15 years. A claim for a 20% reduction in prosthetic failure rate for a pros thesis priced at 2CC would not justify either an RCT or licensing of the prosthesis. The same projected reduction in failure rate with a CE set at 1.2CC, however, would lead to a trial being considered in men under 65 and women under 55 years of age.
The method of Lakatos (1988) can be used to calculate sample size taking account of staggered entry, loss to follow-up through death and different probabilities of fail ure in the new and standard prosthesis groups. Using the two examples given, and assuming loss to follow-up due to death, and recruitment over a two-year period, the number of patients required in the studies, using three different trial designs, are given in Table V . assuming a = 0.05 and 90% power. Evaluation of new components. RCTs which show a significant impact on survivorship to revision are large and expensive to mount, since the need for the earliest possible evaluation of outcome demands a multicentre design with rapid recruitment. A minimum follow-up of 15 years seems necessary for thorough assessment since it is only as revision rates increase that the potential of more effective implants becomes apparent. If new technology was sub jected to a mandatory randomised trial, however, the use of the approach which we have described could lead to per mission for unrestricted marketing as soon as a statistically significant improved performance was established. Alter native outcome measures with early identification of femo ral loosening or acetabular wear would allow a more rapid decision about general release of the new technology but the true survivorship profile would require confirmation by continuing surveillance to a minimum of 15 years. Implications for design, manufacture, marketing and legislation. New designs offer their recipients the unproven possibility of better outcome, but, equally, no certainty that it will not be worse. If the risk of a worse outcome appears small, most surgeons and patients would opt for the possi bility of improved efficacy, providing that neither party has to consider costs. In these circumstances, there is little professional incentive to conduct an RCT.
For the manufacturer the possibility of improved per formance has a market value. Unless there is a regulatory requirement, the decision on whether or not to institute an RCT is an economic one. If the costs of RCT are expected to â€˜pay off' by increasing market share and perhaps market price of the prosthesis, then conducting an RCT will be profitable. If these commercial benefits can be achieved on the basis of possible, but unproven improvement, the addi tional costs of RCT may not be justified. Therefore few randomised trials have been performed. Yet the use of new implant designs outside the context of a rigorous compar ative study can only be justified if cost as well as design and material composition are indeed â€˜substantiallyequiva lent' . Were governments to insist on RCTs before licensing any new components, this would, in the first instance, place the costs of RCTs upon the supplier, who might recover them if the RCT were to establish improved performance.
An alternative approach might be the negotiation between purchaser and supplier of a contractual guarantee of improved performance which, if not met, would result in price adjustment. Such contracts occur in other sectors of commerce.
DISCUSSION
A value-based approach to the assessment of quality in total joint replacement has recently been described as sub jective, lacking well-defined limits, and of little practical guidance (Faro and Huiskes 1992) . We do not agree. Since the performance of a number of prosthetic designs is well established, the opportunities for improvement are clearly defined. Modelling allows rational evaluation of the proba bility of cost-effectiveness of new designs.
The model is sensitive to the actual information which is entered, and, in particular, to the ratio between the total cost of the intervention and the cost of the established prosthetic components. Sensitivity analysis (Table VI) Many countries enforce detailed standards relating to the manufacture, packaging, and sterilisation of prostheses (Faro and Huiskes 1992) , but few demand other than loosely interpreted â€˜substantialequivalence' for prosthetic components. Proof of cost-effectiveness is now mandatory for new drugs and new applications of existing drugs in Australia and elsewhere (Freemantle et al 1995) . The long term outcome of interventions for chronic disease such as joint replacement presents a more difficult problem, since the parties involved cannot wait for long periods before realising the potential of new technology. Use of the din ical trial design which we have described could substan tially shorten the period of evaluation of new designs with a projected survival profile which looks promising enough to test.
Implications for purchasers and providers. The selection of favoured components by surgeons and purchasing poli cies pursued by management should be mutually negotiated with the principles of cost-effectiveness in mind. The mod el indicates that the potential of more expensive but cost effective new components would be realised 10 to 15 years after implantation, and before that time, assessment of cost effectiveness would appear less encouraging. Therefore a commitment to long-term outcome measurement, and to budgeting strategies which take account of distant benefit will be required. In a climate of cost-containment, this may be politically difficult.
The approach which we have described raises profes sional, ethical and political issues. Decisions upon limits to health spending and resource allocation within health lie in the hands of the politicians. Health workers should be free to participate in that debate, but professional responsibility includes a commitment to make the best use of the resour ces that society chooses to allocate. The freedom granted to surgeons to exercise choice depends on the style of health system in which they work. Many see control of that choice as interference in their ability to deliver contemporary standards of care. We believe that choice should not be the subject of government or bureaucratic regulation but a professional decision, based on known outcomes and plau sible alternatives, rather than dictated by fashion or by unproven expectation.
It is the surgeon's role to act on the patient's behalf should there appear to be conflict between managerial goals and the interest of patients. That role reasonably includes consideration of the interests of those candidates for joint replacement who have yet to present, and particularly for those who are waiting for surgery (Smith et al 1990) .
Where limited funds are available for health care, the use of information about cost-effectiveness must influence the choice of prosthesis.
We believe that this model should be used in research and development to allow direction towards increased affordability for a given level of performance.
Increase in prosthetic costs can only be justified by proportional @ improvement in outcome.
No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.
